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Introduction: The use of biomarkers to evaluate the presence of a
target or to select a specific therapy is increasingly advocated. The
correlation of biomarker expression between the primary tumor and
its corresponding metastasis has not yet been well documented and
analyzed in patients with non-small cell lung cancer (NSCLC).
Methods: The expression of epidermal growth factor receptor
(EGFR), excision repair cross-complementing (ERCC1), vascular-
endothelial growth factor receptor, and Ki-67 was immunohisto-
chemically analyzed in tumor samples of primary NSCLC and one
corresponding metastasis in a population of 49 patients.
Results: Sixteen cases (33%) displayed clear discordance in the
EGFR status between the primary tumor and the metastasis, with a
significant trend toward downregulation of EGFR in the metastasis
(p  0.01). The ERCC1 status was discordant in 20 cases (41%),
with a trend toward overexpression in brain and adrenal metastases
(p  0.01 and p  0.08, respectively). The vascular-endothelial
growth factor receptor and Ki-67 statuses were discordant in 13
(27%) and 15 (31%) cases, respectively. No difference in expression
was observed between synchronous and metachronous metastasis.
Conclusion: Biomarker expression is discordant between the pri-
mary tumor and its corresponding metastasis in about one third of
patients with NSCLC. These findings should be considered in the
setting of clinical trials and further explored using frozen material
and high-throughput techniques.
Key Words: Non-small cell lung cancer, Primary tumor, Corre-
sponding metastasis, Biomarker, ERCC1.
(J Thorac Oncol. 2009;4: 1212–1220)
Lung cancer is the leading cause of cancer death in theWestern world, killing more than 1 million people world-
wide each year. In Europe, mortality among women caused
by lung cancer is increasing because more and more women
have been smoking over the past half century. Overall sur-
vival of patients at 5 years is around 14%. Non-small cell
lung cancer (NSCLC) accounts for 80% of lung cancer, and
around 55% of patients are diagnosed with advanced or
metastatic disease.1 The standard treatment for these patients
is systemic chemotherapy containing a platinum agent, but in
recent years, the armamentarium of cancer therapy in patients
with NSCLC has been enriched by the use of antiangiogenic
compounds (bevacizumab) and antiepidermal growth factor
receptor (EGFR) agents (erlotinib and cetuximab).
Advances in the knowledge and understanding of the
molecular pathways related to the etiology and pathogenesis
of cancer have allowed the identification of new therapeutic
targets. These discoveries have led to the development of
therapeutic agents that target key molecules and specific
pathways involved in tumor growth. Some of these molecular
targeted agents are associated with predictive biomarkers of
efficacy, e.g., HER1 expression, mutation, or amplification
for EGFR-targeting compounds, HER2 amplification for tras-
tuzumab, and KIT mutation for imatinib. In parallel, predic-
tive biomarkers associated with response to chemotherapeutic
agents have been identified.2
Two major targets have been identified in NSCLC and
are currently blocked in the clinical setting in patients with
metastases: the EGFR and the VEGF/ vascular-endothelial
growth factor receptor (VEGFR) pathway. EGFR is a trans-
membrane molecule that has been implicated in the develop-
ment and progression of cancer.3 EGFR overexpression is
considered as a poor prognostic factor for survival in patients
with NSCLC. The clinical use of inhibitors of the EGFR
tyrosine kinase domain, such as erlotinib and gefitinib, has
heightened the interest in identifying patients most likely to
benefit from EGFR inhibition. Some studies suggest that
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EGFR expression, and EGFR mutation or the gene copy num-
ber, are correlated with higher response rates and longer surviv-
al.4,5 Another important molecular target in NSCLC is the
VEGFR. Angiogenesis is a key biologic process for tumor
survival and development. This receptor modulates the migra-
tion and proliferation of endothelial cells and the neovasculature
formation in several types of cancer. Its presence is a prognostic
factor in NSCLC, and the high level of expression in this tumor
type was one of the rationales behind testing antiangiogenic
drugs.6 Today, bevacizumab is a key drug in the treatment of
NSCLC, which has yielded improved response and survival rate.
Excision repair cross-complementing (ERCC1) is in-
volved in the repair of DNA damage through the excision of
mismatched nucleotides and their replacement with the corre-
sponding ones.7 The expression of this protein has a prognostic
value in patients with NSCLC who do not receive adjuvant che-
motherapy after curative surgery and predicts a survival benefit of
cisplatin-based adjuvant chemotherapy in treated patients.8,9
Ki-67 is a DNA-binding nuclear protein associated with
cell proliferation. It is a reliable marker of the growth fraction
of a tumor cell population in several tumor types. In NSCLC,
high Ki-67 value may indicate poor survival and greater
sensitivity to chemotherapy.10
At the time of diagnosis of NSCLC or before the
inclusion of a patient in a clinical trial, some of the afore-
mentioned biologic parameters can be immunohistochemi-
cally evaluated in paraffin-embedded blocks. The tumor ma-
terial used to carry out such an analysis can originate either
from a tumor biopsy (the most frequent case) or from a
sample of the primary tumor if the tumor was resected
(20–30% of cases in NSCLC). A limited number of studies
have demonstrated a high correlation between the percentage
of cells stained with Ki-67 and EGFR between bronchial
biopsy specimens and resected tumors.11–14 A study by Tail-
lade et al.,15 which compared biomarker expression of bron-
chial biopsies and the corresponding resected primary tu-
mors, showed discordances in the level of expression of
ERCC1, Ki-67, and EGFR in 9%, 21%, and 18% of the cases,
respectively. This heterogeneity in the expression between
the biopsy specimen and the primary tumor could have a
major impact on the therapeutic strategy.
In the case of unresectable disease at the time of diagnosis,
the treatment strategy is based on the histologic and immuno-
histochemical analysis of the primary tumor or one of its me-
tastases (usually liver, lung, or adrenal masses). The correlation
of biomarker expression between the primary tumor and the
corresponding metastasis has not been adequately studied in
NSCLC. Italiano et al.16 demonstrated differences in the
positive expression of EGFR between the primary tumor and
the metastasis in 33% of their cases analyzed. Another study by
Gow et al.17 showed discordances attaining 27% in EGFR muta-
tions between the primitive tumor and the correspondingmetastasis.
Interestingly, most studies which compared biomarker expression
and genetic characteristics between the primary tumor and the
corresponding metastasis in other solid tumors, such as colon and
breast cancer, have demonstrated a high degree of correlation.18–20
The aim of our study was to identify the potential
changes between the primary tumor and metastasis samples
in the expression of relevant biomarkers and molecular tar-
gets, currently used to define therapeutic strategies in patients
with NSCLC.
PATIENTS AND METHODS
Patients
Between April 1992 and May 2008, 49 patients with
NSCLC, for whommaterial was available both from the primary
tumor and a corresponding metastatic site, were identified from
the Pathology Departments of the Marie Lannelongue Hospital,
Institut Mutualiste Montsouris and the University Hospital of
Nice (France). Fifty-five patients were initially identified
through three pathologic databases.16,21 Six patients were excluded
from the analysis because tumors specimen were not available.
Each patient included had only one matched metastasis.
All primary tumor and metastasis specimens retrieved
were fixed in formalin and embedded in paraffin. Thirty of
the analyzed primary tumors were surgically resected, five
were biopsied by bronchial endoscopy, and three were ob-
tained by CT scan-guided needle punction. The origin of 11
primary tumor biopsies is unknown. Forty metastasis were
surgically resected, whereas nine were obtained by CT scan-
guided needle punction.
Immunohistochemical Procedure
All tissues were reviewed by a senior pathologist (F.P.-L.).
Paraffin-embedded sections of 5 m thickness were deparaf-
finized using xylene and graded series of ethanol.
EGFR Immunohistochemical Staining Method
Immunostaining for EGFR was performed using the
immunohistochemical system kit EGFR pharmDx (Dako-
Cytomation, Carpinteria, CA), on freshly cut, formalin-fixed,
paraffin-embedded tissue. Slides were dried at room temper-
ature for 4 hours and then placed at 57°C overnight. Sections
were deparaffinized in two sequential xylene baths (5 min-
utes), 100% ethanol (3 minutes) and 95% ethanol (3 minutes),
followed by a 5-minute single wash in Wash-Buffer solution
(Dako). The slides were loaded onto an autostainer (Dako),
and the following washes and incubations were applied se-
quentially: 5-minute buffer rinse, 5-minute proteinase K in-
cubation (Dako), 5-minute buffer rinse, 5-minute peroxydase
blocking agent incubation, 5-minute buffer rinse, 30-minute
primary EGFR antibody or negative control reagent incuba-
tion, 5-minute buffer rinse, 30-minute visualization reagent
incubation, two buffer rinses, 5-minute substrate chromogen
solution incubation, and a final buffer rinse. Slides were
removed from the autostainer and counterstained with hema-
toxylin for 10 minutes, then gently rinsed in reagent quality
water. Positive control tissues were used according to the
manufacturer’s instructions. The negative control consisted in
the omission of the primary antibody and incubation with
immunoglobulins of the same species.
VEGFR Immunohistochemical Staining Method
Immunohistochemical staining was performed with the
avidin-biotin-peroxidase complex method. Sections were
briefly immersed in citrate buffer (0.01 mol/l citric acid: pH
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6.0) and were incubated for four 5-minute intervals at 100°C
in a microwave oven for antigen retrieval. The sections were
then incubated with an antiflt-1 antibody (1:200, rabbit poly-
clonal; Santa Cruz Biochemical, Santa Cruz, CA) and an
anti-KDR antibody (1:200, rabbit monoclonal; Santa Cruz
Biochemical). VEGF immunohistochemical staining methods
were performed without microwave pretreatment with an
antihuman VEGF antibody (1:100, polyclonal; Santa Cruz
Biochemical, Santa Cruz, CA). After overnight incubation at
4°C with the primary antibody, slides were washed in phos-
phate-buffered saline and then exposed to the secondary
antibody, a biotinylated antirabbit antibody (1:200; Jackson
Laboratories, West Grove, PA) for 30 minutes at room
temperature. The slides were then washed in phosphate-
buffered saline and incubated with the avidin-biotin-peroxi-
dase complex (1:200; Dako, Glostrup, Denmark) for 30
minutes at room temperature. The chromogenic substrate of
peroxidase was a solution of 0.05% 3,3-diaminobenzidine
tetrahydrochloride/0.03% H2O2/10 mmol/l imidazole in 0.05
mol/l tris buffer. Slides were counterstained with hematoxy-
lin for 10 minutes, then gently rinsed in reagent quality water.
The assay conditions were established with human umbilical
cord vessels as positive controls. Normal rabbit IgG for the
monoclonal or polyclonal antibody, at the same concentration
as the primary antibody, was used as the negative control.
ERCC1 Immunohistochemical Staining Method
A standard protocol was performed for the immuno-
staining of the samples. In brief, for epitope retrieval, spec-
imens were exposed to 10 mM citrate buffer (pH 6.0) and
heated for 60 minutes in a water bath. Tumor sections were
incubated for 60 minutes with a monoclonal antibody specific
against the full-length human ERCC1 protein at a 1:400
dilution (mouse, clone 8F1, Neomarkers). Antibody binding
was detected by means of an ABC kit with NovaRED as the
substrate (Vectastain Elite, Vector Laboratories) and Mayers
hematoxylin as the counterstain. Sections of normal tonsil
tissues were included as external positive controls, and stro-
mal cells surrounding the tumor area served as internal
positive controls.
Ki-67 Immunohistochemical Staining Method
Ki-67 antigen levels were determined using the Ki-67
monoclonal antibody (Dako) with the slides stained accord-
ing to the streptavidin-biotin staining procedure. Briefly, after
deparaffinization, specimens were heated by microwave (four
times at 100°C) in 0.01 M citrate buffer solution. After
cooling gradually to room temperature, the slides were incu-
bated for 20 minutes in 0.3% hydrogen peroxide diluted in
methanol. Slides were then washed with distilled water,
incubated with normal rabbit serum to block nonspecific
binding, and incubated with primary antibody, diluted to
1:500 in buffered solution, for 60 minutes at room tempera-
ture. After incubation with the bridging antibody for 30
minutes, the slides were then incubated with the avidin-biotin
complex for 30 minutes. Immunostaining was visualized by
diaminobenzidine (stained for 8 minutes) and counterstained
with hematoxylin.
Immunohistochemical Evaluation
The presence of tumor cells and the cellularity of the
tumor was confirmed and reviewed by two senior patholo-
gists (F.P.-L. and P.V.). Sections were blind analyzed with
simultaneous dual evaluation and subsequently reviewed by a
senior pathologist (F.P-.L.).
Immunohistochemical staining was read at a 400
magnification, and a score was calculated as follows: score
I  Prop, where I was the intensity staining defined as:
weak  1, moderate  2, strong  3, and Prop was the
fraction of positive cells expressed as a percentage. This
method yielded values from 0 to 300.
To establish positive/negative contingency tables, marker
expression values were dichotomized into negative and pos-
itive, by using already reported and validated cut-off val-
ues.8,16,22,23 For EGFR expression, both the primary and
metastatic neoplasms were considered positive when more
than 10% of the tumor cells had membranous staining.
Specific membrane staining in less than 10% of neoplastic
cells was defined as EGFR-negative.16 Cytoplasmic staining
without associated membrane staining was considered nega-
tive. VEGFR protein expression was considered positive
when membranous immunostaining was seen in at least 10%
of cancer cells.22 For ERCC1, the staining intensity was
graded on a scale of 0 to 3 (with a higher number indicating
a higher intensity and with endothelial cells in tonsil control
tissue used as a reference and assigned an intensity of two).
The percentage of positive tumor nuclei was calculated for
each specimen, and a proportion score was assigned (0 if
0%, 0.1 if 1–9%, 0.5 if 10–49%, and 1.0 if 50% or more).
This proportion score was multiplied by the staining in-
tensity of nuclei to obtain a final semiquantitative H score.
The value of the H score  1 was chosen as the cut-off
point for separating ERCC1-positive tumors from ERCC1-
negative tumors as previously reported.8 For Ki-67, protein
expression was considered positive when 20% of the tumor
nuclei stained positively and was considered negative if
staining was less than 20%.23
Statistical Analysis
The statistical analysis was performed using the SAS
(v9.1) and R (v2.6.1) software. For each biomarker, a 2
test was performed on contingency tables to compare
marker expressions according to the primary/metastasis
status. A Wilcoxon paired test was used for intrapatient
evolution of expression. For graphical representations, the
Log2 of ratio between the metastasis and its corresponding
primary tumor was calculated. So log2 (ratio) less than 0 or
more than 0 indicates a lower or higher expression level,
respectively, in metastasis. For the comparison of dichot-
omized expression values, we calculated the proportion of
discordances between the primary tumor and the related
metastatic sites.
RESULTS
Clinical and Pathologic Features
The characteristics of the 49 patients are described in
Table 1. The median age of the patients at the time of the
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initial diagnosis was 57 years (range, 39–84 years). Forty-
nine metastasis samples were analyzed, including 24 adrenal
and nine brain metastases. Metastases were synchronous in
19 cases (39%) and metachronous in 30 cases (61%). Only
nine of the 30 metachronous cases received adjuvant chemo-
therapy between the diagnosis of the primary and the occur-
rence of metastasis. None of the patients received EGFR-
targeted therapy.
EGFR Status in Primary and Metastatic NSCLC
Tumors
EGFR appeared to be more frequently positive (10%
immunostaining) in primary tumors than in metastasis (38/49
and 28/49, respectively, p 0.052) (Table 2) and with higher
intensities (p  0.01). This was confirmed by individual
patient comparison, which showed a trend toward decreased
expression of EGFR in metastases (Figure 1A). In 35%17 of
patients, the level of EGFR expression was at least fivefold
lower in the metastasis than in the corresponding primary
tumor. No significant difference in EGFR expression was
found between the different metastatic sites.
VEGFR Status in Primary and Metastatic
NSCLC Tumors
No difference was observed in VEGF expression
(10% immunostaining) when primary and metastatic tu-
mors were compared (39/49 and 34/49, respectively, p 
0.35), and intensities were similar in both groups (p  0.81).
Only 12% of patients presented at least a fivefold change in
VEGFR expression in the metastasis (Figure 1B), and there
was no difference in relation to the metastatic site.
ERCC1 Status in Primary and Metastatic
NSCLC Tumors
By considering the ERCC1 H score more than 1 as
positive, the proportion of positive staining was similar in
both primary and metastatic lesions (18/49 and 26/49,
respectively, p  0.155) (Table 2) but with a significantly
higher level of expression in metastatic lesions (p  0.04).
Moreover, individual comparisons showed a general
trend toward increased expression of ERCC1 in metastasis
(Figure 1C), where ERCC1 expression was at least fivefold
higher than in the corresponding the primary tumor for
37% of patients. ERCC1 expression was significantly
higher in brain metastases compared with the correspond-
ing primaries (p  0.01). Higher, but not significant,
ERCC1 expression was also found in adrenal metastases
(p  0.08).
Ki-67 Status in Primary and Metastatic NSCLC
Tumors
No difference was observed in Ki-67 expression when
primary and metastatic lesions were compared, 33 of 48
(69%) and 36 of 48 (75%) exceeded the 20% staining
threshold, respectively (p  0.649) (Table 2). Staining inten-
sities were also similar in both group (p  0.74). However,
29% of patients had at least a fivefold change in Ki-67
TABLE 1. Patients Characteristics (n  49)
No. of
Patients Percentage
Age at diagnosis (yr)
Median 57
Range 33–84
Sex
Male 41 83
Female 8 17
Stage at initial diagnosis (TNM)
I 1 2
II 12 24
III 24 49
IV 12 24
Histology
Adenocarcinoma 23 47
Squamous cell carcinoma 15 31
Large cell carcinoma 6 12
Bronchoalveolar 3 6
Others (neuroendocrine) 2 4
Origin of primary tumor
Surgically resected 30 61
Bronchial endoscopy 5 10
Needle biopsy 3 1
Unknown 11 22
Metastatic sites analyzed
Adrenal gland 24 49
Brain 9 18
Bone 8 16
Soft tissue 3 6
Othera 5 11
Time between diagnosis of the primary tumor
and onset of the metastasis
6 mo 19 39
6 mo 30 61
a Liver (4) and inguinal lymph node (1).
TNM, tumor, node, metastasis.
TABLE 2. Expression of EGFR, VEGFR, ERCC1, and Ki-67
Primary Lung Tumor
(n)
Metastasis
(n)
EGFR
IHC 11 21
IHC 38 28
VEGFR
IHC 10 15
IHC 39 34
ERCC1
IHC 31 23
IHC 18 26
Ki-67
IHC 15 12
IHC 33 36
EGFR, epidermal growth factor receptor; VEGFR, vascular-endothelial growth
factor receptor; ERCC1, excision repair cross-complementing; IHC, immunohistochemistry.
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expression between the primary tumor and the corresponding
metastasis (Figure 1D). No difference in the level of expres-
sion was found in relation to the metastatic site.
Comparison of Biomarkers’ Status Between
Primary Tumors and Metastases
Forty-nine paired primary and metastatic tumors were
available for analysis for each selected biomarker. EGFR
discordance was observed in 16 cases (33%); in 13 cases,
EGFR was expressed in the primary tumor but not in the
metastasis (Figures 2A and 2B), whereas three samples
showed EGFR expression in the metastasis but not in the
primary tumor. Thirteen of 49 paired primary and metastatic
tumors (27%) were discordant for VEGFR expression (Fig-
ures 2E and 2F). Nine of these primary tumors were positive,
whereas the corresponding metastases were negative (Figures
2C and 2D). Discordance was observed in ERCC1 expression
in 20/49 (41%). In 14 cases, ERCC1 was not expressed in
the primary tumor but was positive in the metastasis,
whereas six samples showed ERCC1 expression in the
primary but not in the metastasis. Discordance was ob-
FIGURE 1. Difference in EGFR (A), VEGFR (B),
ERCC1 (C), and Ki-67 (D) expression for each pa-
tient between primary tumor and corresponding
metastasis (expressed in log2 [ratio]; ratio: score
metastasis/score primary). Red represents increase
in expression, and green represents decrease
(both from 0 to 10 fold).
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served in Ki-67 expression in 15/48 cases (31%). In nine
cases, a positive metastasis corresponded to a negative
primary (19%), whereas in six cases, Ki-67 expression was
present in the primary but not in the metastasis (Table 3,
Figures 2G and 2H).
In total, discordance between the primary tumor and
the corresponding metastasis ranged between 26% and
41%. A change toward a decreased expression was ob-
served for EGFR in metastasis, when compared with the
primary tumor, whereas the opposite trend was observed
for ERCC1 expression in metastasis compared with the
primary tumor (Figures 1A and 1C). No particular trend
was identified in the changes in VEGFR and Ki-67 expres-
sion (Figures 1B and 1D).
Five patients (10%) had three discordances, 13 patients
(26%) had two discordances, and 21 patients (43%) had one
discordance among the four biomarkers. Only nine patients
(18%) had no discordances (Table 4).
FIGURE 2. Biomarkers expression
between primary tumor and the cor-
responding metastasis. Panels A and
B, primary tumor with positive mem-
branous staining for epidermal growth
factor receptor (A) and the corre-
sponding negative metastasis (B)
(200 and 100, respectively). Pan-
els C and D, primary tumor with posi-
tive nuclear staining for excision repair
crosscomplementing (C) and the cor-
responding negative metastasis (D)
(200). Panels E and F: primary tu-
mor with membranous staining for
vascular endothelial growth factor re-
ceptor (E) and the corresponding me-
tastasis (F), both positive but with a
diminished VEGFR expression at the
metastatic sample (200). Panels G
and H: primary tumor and corre-
sponding metastasis with nuclear
staining for Ki-67, with a similar level
of Ki-67 expression (200).
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Comparison of the Biomarker Status Between
Primary Tumors and Metastases in Relation to
the Time of Diagnosis of the Metastasis and
Adjuvant Chemotherapy
Nineteen patients with synchronous metastases (diag-
nosed 6 months from the diagnosis of the primary) and 30
patients with metachronous metastases (6 months). The
discordance in biomarker expression between the primary
tumor and the corresponding metastasis was similar in both
cases (Table 5).
Nine of the patients with metachronous metastases
received cisplatin-based chemotherapy between the date of
surgical excision of the primary and the date of the diagnosis
of metastasis. When those patients were excluded from the
analysis, the changes in EGFR expression between the pri-
mary and the metastatic site remained significant. No signif-
icant changes were observed when treated patients were
excluded with respect to ERCC1 expression.
DISCUSSION
The aim of our study was to compare immunohisto-
chemical expression of four biomarkers (i.e., molecular tar-
gets) between the primary tumor and corresponding metasta-
ses. To the best of our knowledge, this study is the first to
compare ERCC1, VEGFR, and Ki-67 in primary NSCLC and
their distant metastases. This is also one of the largest series
comparing EGFR expression between primary and metastatic
lesions.
In the era of molecular-targeted therapies and “tailored”
treatments, the analysis of several biomarkers in a newly
diagnosed NSCLC may become mandatory to choose the best
treatment for the patient. Moreover, the analysis of biomarker
expression is increasingly performed before including pa-
tients in clinical trials in NSCLC. This strategy is now an
integral part of several retrospective and some prospective
analyses, notably for EGFR and ERCC1. In the analysis of
studies testing gefitinib or erlotinib, both EGFR tyrosine
kinase inhibitors yielded a significant survival benefit in
patients with EGFR-positive lesions.4,24,25 The International
Adjuvant Lung Trial—Bio study showed that ERCC1 is a
marker of resistance to platin-based chemotherapy in resected
patients.8 Very ambitious on-going studies, such as the Bio-
marker-based Approaches of Targeted Therapy for Lung
Cancer Elimination program at the MD Anderson Cancer
Center, are based on a strategy, analyzing EGFR and
VEGFR, among other biomarkers, to choose the most appro-
priate therapy.
A major concern of this “tailored” strategy is which
tumor tissue should be analyzed to accurately represent tumor
behavior, notably in the metastatic setting. In most clinical
trials including patients with advanced NSCLC, no informa-
tion is given about the site of origin of the tumor material,
and, in many cases, the material analyzed could precede by
several months or years the disease under treatment in the
trial. This uncertainty raises the question of the stability of the
expression of different biomarkers during the metastatic pro-
cess and the implications for treatment strategies.
Our study revealed discordances in biomarker expres-
sion between the primary tumor and the corresponding me-
tastases in about one third of the cases. Consequently, one
could presume that the immunohistochemical analyses of the
primary tumor may provide misleading information to guide
the therapeutic strategy in the metastatic setting where sur-
vival is mostly linked to the behavior of metastases. Interest-
ingly, in only nine cases (18% of the study population) we
observed truly consistent expression results between primary
and metastasis across the four antibodies evaluated. This may
take into account two phenomena: intratumor heterogeneity
within a single sample12,15 and biologic changes between the
formalin fixed primary tumor and its corresponding metastasis.
Our findings were discordant for EGFR in 33% of cases
between the primary and metastatic samples. This finding is
consistent with other series, such as the one by Italiano et al.16
who found that 33.3% of results were discordant in EGFR
immunohistochemical expression and 27% in the EGFR sta-
tus by in situ hybridization. Similar figures were presented by
Sun et al.,26 Bozetti et al.,12 and Gow et al.17 with discordant
results in 22%, 32%, and 27% of cases, respectively, in the
EGFR gene copy number and mutations between the primary
tumor and corresponding metastasis. In our study, the inten-
sity score for EGFR expression showed a significant trend
toward lower expression in metastases compared with the
primary tumor, which reached a fivefold reduction in 35% of
the patients. Even if our scoring system was different, this
finding is in line with the study by Italiano et al.,16 which
showed discordance between a positive primary and a nega-
tive metastasis in 23.3% of cases. As shown by Des Pas et
al.27 no difference in EGFR status or level of expression was
observed in patients before and after chemotherapy.
TABLE 3. EGFR, VEGFR, ERCC1, and Ki-67 Status Correlation Between Primary Tumor and Corresponding
Metastatic Sites
Primary Lung Tumor Status/Metastasis Status
Positive/Positive
n (%)
Negative/Negative
n (%)
Positive/Negative
n (%)
Negative/Positive
n (%) Discordance (%)
EGFR 25 (51) 8 (16) 13 (27) 3 (6) 33
VEGFR 30 (61) 6 (12) 9 (18) 4 (8) 26
ERCC1 12 (24) 17 (35) 6 (12) 14 (29) 41
Ki-67 27 (56) 6 (13) 6 (13) 9 (19) 32
EGFR, epidermal growth factor receptor; VEGFR, vascular-endothelial growth factor receptor; ERCC1, excision repair cross-complementing.
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The results were discordant in 41% of cases for ERCC1
expression between primary and metastatic lesions. To our
knowledge, this is the first time that this type of analysis has
been performed. Even if most of the knowledge about resis-
tance to platin-based chemotherapy and ERCC1 comes from
the adjuvant setting, there is an increased interest in translat-
ing these findings, so that they may be beneficial to patients
with metastatic disease. Our finding raises the question of
whether both the primary and the metastasis should be bi-
opsed before deciding to withhold platin-based chemotherapy
in patients with a positive ERCC1 status. We found increased
ERCC1 expression in both brain and adrenal metastases
compared with the corresponding primary tumor and other
metastatic sites, based on the expression intensity score. This
difference could be related to the fact that both sites were the
most represented in our population. A more general trend
could not be excluded because of the small number of cases
with other metastatic sites. No difference in ERCC1 expres-
sion was found between synchronous and metachronous me-
tastasis or in case of prior chemotherapy.
A discordant rate of 27% was found for VEGFR ex-
pression between primary tumor and the paired metastasis.
The difference in the expression intensity score between
paired primary/metastasis was not as strong as that of the
other biomarkers, with less than 12% of patients exhibiting a
fivefold change in expression.
Ki-67 results were discordant in 31% of cases. The
cut-off value of 20% was already validated as a strong
prognostic factor in lung cancer.23 It was also proposed in a
recent meta-analysis by Martin et al.10 as a potential value
useful for chemotherapy trials, as it allows selecting tumors
with a high replication rate. Thirty percent of patients
exhibited a wide difference in the expression intensity
score between the primary tumor and metastasis. Only
three patients received adjuvant chemotherapy in this
group. The other six patients who received adjuvant che-
motherapy did not exhibit major changes. Our study is the
first to compare biomarker expression in synchronous and
metachronous metastases in NSCLC. In contrast with what
we expected, the time between the diagnosis of the primary
TABLE 4. Biomarkers’ Status Discordance Regarding
Positive Expression
Patient EGFR VEGFR ERCC1 Ki-67
1
2
3
4
5
6
7
8
9
10
11
12
13     
14    
15
16
17
18
19
20
21
22
23
24     
25
26
27
28    
29     
30
31
32
33
34
35
36
37
38     
39     
40     
41    
42
43
44     
45
46
47
48
49
Each black square means discordance in positivity between the primary tumor and
the corresponding metastasis. White square means concordance between the primary
tumor and the corresponding metastasis. Gray means not available.
EGFR, epidermal growth factor receptor; VEGFR, vascular-endothelial growth
factor receptor; ERCC1, excision repair cross-complementing.
TABLE 5. EGFR, VEGFR, ERCC1, and Ki-67 Status
Discordance (Primary Tumor Status/Metastasis Status 
Positive/Negative or Negative/Positive) Related to the Time
Between Primary and Metastatic Diagnosis
Time Between Diagnosis of the
Primary Tumor and Onset of
the Metastasis
<6 mo >6 mo
n % n %
Discordance of EGFR status 7 37 9 30
Discordance of VEGFR status 4 21 9 30
Discordance of ERCC1 status 8 41 12 40
Discordance of Ki-67 status 6 32 9 31
EGFR, epidermal growth factor receptor; VEGFR, vascular-endothelial growth
factor receptor; ERCC1, excision repair cross-complementing.
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tumor and of the corresponding metastasis did not signif-
icantly change the degree of discordance.
One limitation of our study is that immunohistochem-
ical analysis is not a strictly a quantitative method. Different
scores and cut-off values exist and the interpretation of
staining intensity remains partly subjective. Moreover, the
biologic impact of a different level of biomarker expression
in the primary tumor and the metastasis remains unclear, even
if both are on the “positive” side.
As most of the tumor samples were formalin-fixed
paraffin-embedded blocks (and sometimes Bouin fixed) we
were unable to adequately address the mutation status of
EGFR and other relevant biomarkers such as K-RAS. Further
transcriptome analysis or copy number alterations were not
evaluated in our population for the similar reasons.
Another limitation is the high rate of adrenal metastasis
and the low rate of liver and lung metastasis in the population
with metastasis.
The potential implications of our findings still need to
be confirmed by prospective studies, to choose the best
treatment options for our patients.
In conclusion, biomarker expression in the primary
tumor and the corresponding metastasis is discordant in
about 30% of patients, with a significant trend toward
downregulation of EGFR and overexpression of ERCC1
between the primary tumor and the metastatic lesion.
Additionally, more sophisticated techniques such as mu-
tation analysis, CGH, and transcriptome analysis of such
samples should be performed in such samples, when tissue
fixation allows such an approach.
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